Constipation Pipeline Review H2 2017 provides an overview of the Constipation (Gastrointestinal) pipeline landscape. Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. Pharmaceutical and Healthcare latest pipeline guide Constipation – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Purchase This Microscopic Polyangiitis (MPA) Pipeline Review H2 2017 Report of 41 Pages with Company profiles and Pipeline Drugs Analysis at http://www.reportsnreports.com/purchase.aspx?name=1125827 .
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 10, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecule, respectively. Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Get Discount on This Report at: http://www.reportsnreports.com/contacts/discount.aspx?name=1125827 .
The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal) and reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. Report covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages also features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. Report reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlist all their major and minor projects.
Report Includes Constipation Pipeline By Companies including: Albireo Pharma Inc, Allergan Plc, Ardelyx Inc, Astellas Pharma Inc, Braintree Laboratories Inc, Dong-A ST Co., Ltd., EA Pharma Co Ltd, Ironwood Pharmaceuticals Inc, Johnson & Johnson, Kissei Pharmaceutical Co Ltd, NGM Biopharmaceuticals Inc, RaQualia Pharma Inc, Sanwa Kagaku Kenkyusho Co Ltd, SK Biopharmaceuticals Co Ltd, Sucampo Pharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Synergy Pharmaceuticals Inc, Synthetic Biologics Inc, Torrent Pharmaceuticals Ltd, Vanda Pharmaceuticals Inc, Yuhan Corp, Zensun (Shanghai) Sci & Tech Co Ltd
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441